

Hôpital du Valais Spital Wallis



# Does a hospital formulary system impact timely medication administration and quality of patient care ?

A.-V. Putallaz<sup>\*1</sup>, V. Jordan-von Gunten<sup>1</sup>, P.-A. Petignat<sup>2</sup>, P. Turini<sup>3</sup>, J. Beney<sup>1</sup>

<sup>1</sup> Division of pharmacy, Institut central des hôpitaux, <sup>2</sup> Division of internal medicine, <sup>3</sup> Medical coordinator for quality of care and patient safety, Hôpital du Valais, Sion, Switzerland

### INTRODUCTION

The prevalence of drug omission is often underestimated but its impact can be clinically relevant

Hypothesis: Delays in administering non-formulary/non-stored drugs could impair the quality of care

Aims:

1° Determine the time between the first prescribed dose and its actual first administration and calculate the number of omitted doses

2° Analyze the clinical relevance of the identified delays

## METHOD

- ☆ Retrospective descriptive 3 months survey of patients hospitalized on the internal medicine wards
- Network of 4 hospitals supplied by a centralized pharmacy located in one of the sites
- Identification of prescriptions through query in electronic records

#### Main outcome measures:


 Median time between the first prescribed dose and its first administration
 Categorization of patient's harm caused by the delays of time-critical drugs<sup>1,2,3</sup> (NCC-MERP taxonomy of medication errors)

## CONCLUSION

- Non-stored/non-formulary drugs take more time to be delivered than formulary drugs, but
   >95% of formulary drugs and 90% of nonstored/non-formulary drugs are administered within 24h following their prescription
- None of the 17 patients who experienced delays underwent severe harm
- No systematic cause of omission was identified

## RESULTS

- 1° Analysis of 16'954 prescriptions :
- Median time to administration < 1h for both non-stored/ non formulary and formulary drugs



 Further studies should focus on all dose omissions during hospitalization

**2°** A delay of **≥ 1,5 omitted dose** was found for 332 prescriptions (**1.96%**)

Of them, only **17** cases were time-critical drugs and considered for potential **clinical relevance** (NCC-MERP categories C-I)

Central site	Enoxaparin*, Acetylsalicylic acid (2x), Ranolazine, Ceftriaxone, Ciprofloxacine, Aciclovir, Levidopa/Carbidopa <sup>#</sup>
Site 1	Enoxaparine, Clarithromycine, Levodopa/Benserazide
Site 2	Gabapentine, Levodopa/Benserazide*
Site 3	Ticagrelor, Levodopa/Benserazide (2x)

<u>Table1</u>: Distribution of identified potentially clinically relevant cases of omission. 2 patients\* required monitoring to confirm that it resulted in no harm and for 1 patient<sup>#</sup>, the error may have contributed to temporary harm and required intervention

#### REFERENCES

[1] Nurs Crit Care. 2010 May-Jun;15(3):112-7
[2] Aust Crit Care. 2011 Feb;24(1):49-52
[3] Arch Intern Med. 2002 Sep 9;162(16):1897-903

<u>Figure 1</u>: Proportion of drugs and their time to administration for formulary (n=15'608) and non-stored/non-formulary (n=1346) drugs for the 4 hospital sites

This work was carried out during the 1st author's postgraduate training in clinical pharmacy, supported in part by pharmaSuisse (www.pharmasuisse.org). There is no conflict of interest to declare.

ESCP Annual Symposium 2016 – 5-7 October 2016 – Oslo, Norway Réf: HP-PC140

johnny.beney@hopitalvs.ch www.hopitalvs.ch/pharmadoc - Service de Pharmacie, ICHV, Avenue du Grand-Champsec 86, 1951 Sion, Suisse